Related Experiment Video
Updated: Jun 9, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
ABCG2 Gene Expression in Non-Small Cell Lung Cancer
Agnieszka Jeleń1,2, Marta Żebrowska-Nawrocka1,2, Mariusz Łochowski3
1Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.
Abstract:
Background/Objectives: ATP-binding cassette subfamily G member 2 [ABCG2/breast cancer resistance protein (BCRP)] contributes to mechanisms of multidrug resistance (MDR) and is a marker of side population (SP) cells in human cancers. The primary objective of this study was to investigate the impact of ABCG2 gene expression on the non-small cell lung cancer (NSCLC) development, course of cancer disease, and patient prognosis using publicly available data. Obtained results were supplemented with assessment of ABCG2 expression in blood of NSCLC patients. Methods: The dataset of lung cancer was analyzed utilizing the TIMER 2.0, UALCAN, TNMplot, MEXPRESS, cBioPortal, MethSurv, KM Plotter, STRING, and ShinyGO 0.80 databases. Blood samples from 50 patients were assessed using the real-time PCR method. Results: The ABCG2 gene was expressed at a low level in NSCLC, and did not correlate with clinical aggressiveness of lung cancer. Higher ABCG2 expression improved overall survival, but only in LUAD. In addition, CpG sites located on the CpG island affecting the NSCLC patient's prognosis were indicated. In the case of our own laboratory results, the study did not reveal any changes in the ABCG2 expression levels in blood collected from patients at different time points during the diagnostic-therapeutic procedure. In the in silico analysis, most ABCG2 protein interactors were associated with the development of drug resistance. Conclusions: ABCG2 appears to have a particularly significant impact on the survival of patients with lung cancer and on the effect of immunotherapy related to immune cell infiltration. Presented findings may support personalized medicine strategies based on bioinformatics findings.
Insights
The ATP-binding cassette subfamily G member 2 (ABCG2) gene shows low expression in non-small cell lung cancer (NSCLC) but higher expression correlates with improved survival in certain lung adenocarcinoma (LUAD) patients. ABCG2 impacts lung cancer prognosis and immunotherapy response.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- ATP-binding cassette subfamily G member 2 (ABCG2), also known as breast cancer resistance protein (BCRP), is implicated in multidrug resistance and cancer stem cell markers.
- ABCG2's role in non-small cell lung cancer (NSCLC) development, progression, and patient outcomes requires further elucidation.
Purpose of the Study:
- To investigate the impact of ABCG2 gene expression on NSCLC development, disease course, and patient prognosis.
- To analyze ABCG2 expression in NSCLC patients' blood and its correlation with clinical parameters.
- To explore ABCG2 protein interactions and their association with drug resistance.
Main Methods:
- Utilized multiple bioinformatics databases (TIMER 2.0, UALCAN, TNMplot, MEXPRESS, cBioPortal, MethSurv, KM Plotter, STRING, ShinyGO 0.80) for in silico analysis of lung cancer datasets.
- Assessed ABCG2 expression in blood samples from 50 NSCLC patients using real-time PCR.
- Analyzed CpG island methylation affecting NSCLC prognosis.
Main Results:
- ABCG2 was expressed at low levels in NSCLC and did not correlate with clinical aggressiveness.
- Higher ABCG2 expression was associated with improved overall survival specifically in lung adenocarcinoma (LUAD) patients.
- No significant changes in blood ABCG2 expression levels were observed during the diagnostic-therapeutic procedure in NSCLC patients.
- In silico analysis revealed that most ABCG2 protein interactors are linked to drug resistance mechanisms.
Conclusions:
- ABCG2 significantly influences lung cancer patient survival and immunotherapy effectiveness, particularly concerning immune cell infiltration.
- Findings suggest potential for personalized medicine strategies in NSCLC based on ABCG2 expression and bioinformatics data.
- ABCG2's role in LUAD prognosis warrants further investigation for targeted therapeutic approaches.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Related Concept Videos
01:58Cell Specific Gene Expression
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...